Reply

Ophthalmology. 2019 Mar;126(3):e24-e25. doi: 10.1016/j.ophtha.2018.12.005.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adalimumab
  • Arthritis, Juvenile*
  • Cost-Benefit Analysis
  • Humans
  • Uveitis*

Substances

  • Adalimumab